Arlyesterase activity of Paraoxonase-1 enzyme in Iraqi patients with β-thalassemia minor

Annals of Tropical Medicine and Public Health

Volumn 22, Issue 8, 2019, Pages

  Al Ani, Ali W ^a   Fadel, Shaema S ^a  

^a UNIVERSITY OF BAGHDAD   (Iraq)

Author keywords

Arylesterase; Lipid profile; Paraoxonase 1; RBC; WBC; thalassemia minor

Indexed keywords

EID: 85079530613     PISSN: 17556783     EISSN: 09746005     Source Type: Journal    
DOI: 10.36295/ASRO.2019.220820     Document Type: Article

References (38)

1. Abdalla MY, et al. Increased oxidative stress and iron overload in Jordanian β-thalassemic children. Hemoglobin 2011; 35(1): 67-79.
2. Galanello R and Origa R. Beta-thalassemia. Orphanet J Rare Dis 2010; 5: 11.
3. Gullu H, et al. Coronary Microvascular function, Peripheral Endothelial Function and Carotid IMT in beta-thalassemia minor. Thromb Res 2013; 131(6): e247-52.
4. Lazarte SS, et al. Foxo3 gene expression and oxidative status in beta-thalassemia minor subjects. Revista brasileira de hematologia e hemoterapia 2017; 39(2): 115-121.
5. Chamaidi A, et al. Favorable Pulse Wave Augmentation Indices and Left Ventricular Diastolic Profile in beta-Thalassemia Minor. Angiology 2017; 68(10): 899-906.
6. Wintrobe MM and Greer J. Wintrobe’s clinical hematology. Lippincott Williams & Wilkins.
7. Engelmann, B. and Massberg, S.(2013) Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013.
8. Acton QA. Hydroxamic Acids: Advances in Research and Application. 2011.
9. Schwartz, M.W., The 5 minute pediatric consult. Lippincott Williams & Wilkins; 2012.
10. Torre DM, et al. Kochar's clinical medicine for students. Lippincott Williams & Wilkins; 2009.
11. Isik Balci Y, et al. Pentraxin-3 levels in beta thalassemia major and minor patients and its relationship with antioxidant capacity and total oxidant stress. Journal of pediatric hematology/oncology 2016; 38(1): 12-16.
12. Allegra S, et al. The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients. The Pharmacogenomics Journal 2019. pp. 1.
13. Labib HA, et al. Paraoxonase-1 and oxidative status in common Mediterranean beta-thalassaemia mutations trait, and their relations to atherosclerosis. J Clin Pathol 2011; 64(5): 437-42.
14. del Carmen Xotlanihua-Gervacio M, et al. Relationship between internal and external factors and the activity of PON1. Environmental Science and Pollution Research 2019. pp. 1-12.
15. Costa LG, et al. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 2005; 69(4): 541-50.
16. de la Iglesia R, et al. Arylesterase activity is associated with antioxidant intake and paraoxonase-1 (pon1) gene methylation in metabolic syndrome patients following an energy restricted diet. EXCLI Journal 2014; 13: 416.
17. Angayarkanni N, et al. Serum PON1 arylesterase activity in relation to hyperhomocysteinaemia and oxidative stress in young adult central retinal venous occlusion patients. Eye (Lond) 2008; 22(7): 969-74.
18. Macharia M, et al. The growing importance of PON1 in cardiovascular health: a review. Journal of Cardiovascular Medicine 2012; 13(7): 443-453.
19. Bednarz-Misa I, et al. Cardiovascular Insufficiency, Abdominal Sepsis, and Patients’ Age Are Associated with Decreased Paraoxonase-1 (PON1) Activity in Critically Ill Patients with Multiple Organ Dysfunction Syndrome (MODS). Disease markers 2019.
20. Utangac MM, et al. Paraoxonase and arylesterase activity in bladder cancer. Turk J Urol 2017; 43(2): 147-151.
21. Unal E, et al. Paraoxonase and arylesterase activities, lipid profile, and oxidative damage in experimental ischemic colitis model. Gastroenterol Res Pract 2012. pp. 979506.
22. Eren E, et al. Serum paraoxonase/arylesterase activity and oxidative stress status in children with metabolic syndrome. Journal of Clinical Research in Pediatric Endocrinology 2014; 6(3): 163.
23. Zsíros N, et al. Paraoxonase-1 arylesterase activity is an independent predictor of myeloperoxidase levels in overweight patients with or without cardiovascular complications. Clinical Biochemistry 2016; 49(12): 862-867.
24. Khalil A, et al. The role of paraoxonase 1 in regulating HDL functionality during aging. 2019.
25. Numan AW. Study of total peroxidase enzymes activities and some trace elenments in patients with breast tumors. Iraqi Journal of Biotechnology 2010; 9(4): 828-837.
26. Hasan HR and Numan AW. Biochemical study of superoxide dismutase enzyme in patients with different brain tumors. 2010.
27. Okuturlar Y, et al. Serum paraoxonase 1 activity in patients with iron deficiency anemia. Archives of Medical Science AMS 2016; 12(4): 697.
28. Levy D, Reichert CO, Bydlowski SP. Paraoxonases Activities and Polymorphisms in Elderly and Old-Age Diseases: An Overview. Antioxidants 2019; 8(5): 118.
29. Macharia M, et al. Indices of paraoxonase and oxidative status do not enhance the prediction of subclinical cardiovascular disease in mixed-ancestry South Africans. Oxidative medicine and cellular longevity 2014.
30. Selek S, et al. Oxidative status and serum PON1 activity in beta-thalassemia minor. Clin Biochem 2007; 40(5-6): 287-91.
31. Kotur-Stevuljevic J, et al. Oxidative stress and paraoxonase 1 status in acute ischemic stroke patients. Atherosclerosis 2015; 241(1): 192-198.
32. Islam MO, Bacchetti T, Ferretti G. Alterations of Antioxidant Enzymes and Biomarkers of Nitro-oxidative Stress in Tissues of Bladder Cancer. Oxidative medicine and cellular longevity 2019.
33. Arenas M, et al. Paraoxonase-1 activity in patients with cancer: A systematic review and meta-analysis. Critical reviews in oncology/hematology 2018; 127: 6-14.
34. Kennedy DJ, et al.Diminished antioxidant activity of high‐density lipoprotein–associated proteins in chronic kidney disease. Journal of the American Heart Association 2017; 2(2): e000104.
35. Pazdzior M, et al. The Oxidative Stress in Knee Osteoarthritis Patients. An Attempt of Evaluation of Possible Compensatory Effects Occurring in the Disease Development. Medicina (Kaunas) 2019; 55(5).
36. Paragh G, et al. Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia. European archives of psychiatry and clinical neuroscience 2002; 252(2): 63-67.
37. Mihajlovic M, et al. Changes in lecithin: cholesterol acyltransferase, cholesteryl ester transfer protein and paraoxonase-1 activities in patients with colorectal cancer. Clinical biochemistry 2019; 63: 32-38.
38. Wedi B, et al. Eosinophil apoptosis is mediated by stimulators of cellular oxidative metabolisms and inhibited by antioxidants: involvement of a thiol-sensitive redox regulation in eosinophil cell death. Blood 1999; 94(7): 2365-2373.